-

10:02:24 PM

IONS Stock News

IONS - Ionis Pharmaceuticals Inc

11/14/22 6:05 AM

Nasdaq : IONS

partnership

Ionis partners with Metagenomi to add gene editing to its broad technology platform

Collaboration with a leader in gene editing systems is Ionis' latest move to expand and diversify its technology CRISPR-Cas gene editing is a natural extension of Ionis' innovative approach to delivering potentially transformative therapies Ionis to hold webcast Nov. 14 at 8 a.m. Eastern Time

RHEA-AI

very positive

11/13/22 1:01 PM

Nasdaq : IONS

clinical trial

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension

RHEA-AI

neutral

11/10/22 7:05 AM

Nasdaq : IONS

conferences

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:Guggenheim 4 th Annual Immunology and Neurology Day on Monday, November 14, 2022 Stifel 2022

RHEA-AI

neutral

11/09/22 7:00 AM

Nasdaq : IONS

earnings

Ionis reports third quarter financial results

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of

RHEA-AI

positive

11/08/22 10:57 AM

Nasdaq : IONS

clinical trial

Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBV

RHEA-AI

neutral

11/07/22 7:05 AM

Nasdaq : IONS

clinical trial

Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from

RHEA-AI

neutral

11/04/22 7:05 AM

Nasdaq : IONS

Ionis announces positive results from fesomersen development program

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results

RHEA-AI

neutral

10/26/22 7:05 AM

Nasdaq : IONS

earnings

Ionis to hold third quarter 2022 financial results webcast

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9 th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022.The webcast may be accessed at

RHEA-AI

neutral

10/12/22 7:05 AM

Nasdaq : IONS

Ionis announces plan for new manufacturing facility in Oceanside, Calif.

Larger facility will significantly increase Ionis' development chemistry and manufacturing capabilities Sudberry Properties will build the facility and lease to Ionis for 20-plus years; Ionis retains option to renew and right of first offer to purchase the property CARLSBAD, Calif. , Oct. 12, 2022

RHEA-AI

neutral

09/23/22 2:25 AM

Nasdaq : IONS

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

IONS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.ionispharma.com
CeoBrett Monia
Security nameIonis Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees757
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2855 Gazelle Ct
StateCalifornia
CityCarlsbad
Zip92010-6670
CountryUS
Phone17609319200

About Ionis Pharmaceuticals Inc

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.